General
Preferred name
LAMIVUDINE
Synonyms
CPD000466319 ()
BCH-189 ()
GR109714X ()
Triumeq-lamivudine ()
Lamivudine (BCH-189) ()
GR109714X, BCH-189 ()
Epivir-Hbv ()
NSC-760061 ()
Zeffix ()
Epivir ()
GR 109714X ()
GR-109714X ()
BCH 189, (-)- ()
Lamivudine teva ()
Virolam ()
Lamivudinum ()
P&D ID
PD002940
CAS
134678-17-4
1117764-41-6
Tags
prodrug
natural product
drug
available
Approved by
PMDA
EMA
FDA
First approval
1995
Drug Status
investigational
approved
Drug indication
Antiviral
Chronic HBV infection
Human immunodeficiency virus infection
Human immunodeficiency virus-1 infection
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV) to disrupt viral DNA synthesis. When phosphorylated, lamivudine can form active metabolites that compete for incorporation into viral DNA. Via DNA incorporation, lamivudine metabolites competitively inhibit the activity of the HIV reverse transcriptase enzyme and act as a chain terminator of DNA synthesis. Due to the lack of a 3'-OH group, incorporated nucleoside analogues prevent the formation of a 5' to 3' phosphodiester linkage that is essential for DNA chain elongation.
DESCRIPTION
Lamivudine is an antiretroviral drug. It inhibits HIV-1 reverse transcriptase, and it belongs to the nucleoside reverse transcriptase inhibitors (NRTI) class of antiretriviral drugs.
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
6
Organisms
11
Compound Sets
26
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
Bioprocess diversity set
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
49
Molecular Weight
229.05
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
2
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
1
cLogP
-0.59
TPSA
90.37
Fraction CSP3
0.5
Chiral centers
2.0
Largest ring
6.0
QED
0.7
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Biological process
Protein degradation
Pathway
Microbiology&virology
Anti-infection
Target
Reverse Transcriptase
NRT inhibitor
HBV
HIV
COVID-19,Reverse Transcriptase
Member status
member
MOA
Reverse Transcriptase Inhibitors
nucleoside reverse transcriptase inhibitor
Indication
human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS), hepatitis B
Biosynthetic Origin
Nucleoside
Therapeutic Indication
Antiviral
Therapeutic Class
Anti-HIV Agents
Source data
